Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)
Others
Ratios

Bioadaptives (BDPT) Income from Continuing Operations (2019 - 2025)

Historic Income from Continuing Operations for Bioadaptives (BDPT) over the last 7 years, with Q3 2025 value amounting to -$379502.0.

  • Bioadaptives' Income from Continuing Operations fell 90800.02% to -$379502.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.1 million, marking a year-over-year decrease of 16846.43%. This contributed to the annual value of -$694068.0 for FY2024, which is 7714.31% down from last year.
  • Bioadaptives' Income from Continuing Operations amounted to -$379502.0 in Q3 2025, which was down 90800.02% from -$157914.0 recorded in Q2 2025.
  • Bioadaptives' 5-year Income from Continuing Operations high stood at -$34516.0 for Q3 2021, and its period low was -$491903.0 during Q1 2021.
  • For the 5-year period, Bioadaptives' Income from Continuing Operations averaged around -$204103.7, with its median value being -$171151.0 (2022).
  • As far as peak fluctuations go, Bioadaptives' Income from Continuing Operations skyrocketed by 8092.29% in 2023, and later crashed by 90800.02% in 2025.
  • Over the past 5 years, Bioadaptives' Income from Continuing Operations (Quarter) stood at -$308336.0 in 2021, then skyrocketed by 62.1% to -$116851.0 in 2022, then grew by 13.79% to -$100734.0 in 2023, then plummeted by 244.51% to -$347036.0 in 2024, then dropped by 9.36% to -$379502.0 in 2025.
  • Its Income from Continuing Operations was -$379502.0 in Q3 2025, compared to -$157914.0 in Q2 2025 and -$258795.0 in Q1 2025.